Myrcludex B is an experimental drug for the treatment of hepatitis B and D. The hepatitis B virus uses its surface lipopeptide pre-S1 for docking to mature liver cells via their sodium/bile acid cotransporter (NTCP) and subsequently entering the cells. Myrcludex B is a synthetic N-acylated pre-S1 that can also dock to NTCP, blocking the virus's entry mechanism.
Myrcludex B is a synthetic lipopeptide compound renowned for its role as a potent entry inhibitor targeting the sodium taurocholate co-transporting polypeptide (NTCP), a key receptor involved in the cellular uptake of hepatitis B and D viruses. Structurally derived from the preS1 domain of the hepatitis B virus large envelope protein, Myrcludex B features an N-terminal myristoylation that enhances its membrane affinity and biological efficacy. Its unique mechanism of action and robust receptor specificity have made it a valuable tool in virology, hepatology, and membrane protein research, offering insights into viral-host interactions and NTCP-mediated processes.
Viral Entry Mechanism Studies: Myrcludex B serves as a critical molecular probe in elucidating the mechanisms of viral entry, particularly for hepatitis B and D viruses. By selectively binding to NTCP on hepatocyte surfaces, it effectively blocks the interaction between viral particles and their target cells. Researchers utilize the peptide to dissect the initial steps of viral attachment and fusion, enabling a deeper understanding of host-pathogen dynamics and the molecular determinants of viral tropism. Such studies are fundamental for advancing antiviral strategy development and for mapping the structural requirements of NTCP-mediated viral entry.
NTCP Function and Inhibition Research: The compound is widely employed in fundamental research to investigate the physiological and pharmacological roles of NTCP in hepatic biology. By acting as a specific NTCP antagonist, it allows scientists to modulate bile acid transport and study the downstream effects on hepatic metabolism and signaling pathways. These applications are instrumental in clarifying the broader biological functions of NTCP beyond its role as a viral receptor, providing a basis for exploring transporter-related liver diseases and drug interactions.
Membrane Protein Interaction Analysis: Myrcludex B offers a robust experimental tool for characterizing membrane protein-ligand interactions within the context of lipid bilayers. Its lipopeptide structure and high affinity for NTCP facilitate the study of protein dynamics, binding kinetics, and conformational changes at the cell surface. Such analyses are valuable for biophysical investigations, screening of potential NTCP modulators, and advancing the understanding of membrane protein pharmacology.
Antiviral Screening Platforms: In preclinical research settings, Myrcludex B is utilized as a reference inhibitor in cell-based assays designed to screen for novel compounds that block hepatitis B and D virus entry. Its well-characterized inhibitory profile provides a benchmark for evaluating the efficacy of experimental antivirals and for optimizing assay conditions. This application supports the identification and validation of new molecular entities targeting the early stages of viral infection, thereby accelerating antiviral discovery pipelines.
Peptide Engineering and Delivery Studies: The distinctive structure of Myrcludex B, characterized by its myristoylated peptide backbone, makes it an exemplary model for investigating strategies in peptide engineering and targeted delivery. Researchers leverage its physicochemical properties to study membrane anchoring, peptide stability, and intracellular trafficking, informing the rational design of next-generation lipopeptide therapeutics and delivery vectors. These studies contribute to the broader field of peptide-based drug design and the development of innovative molecular tools for biomedical research.
1. SERS spectrum of the peptide thymosin‐β4 obtained with Ag nanorod substrate
3. Immune responses to homocitrulline-and citrulline-containing peptides in rheumatoid arthritis
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More